- Pfizer Canada and BioNTech have received Health Canada authorization for the XFG variant-adapted Comirnaty COVID-19 vaccine for active immunization of individuals 6 months and older for the 2026–2027 season.
- The updated formulation targets the Omicron XFG lineage, aligning with public health recommendations to more closely match contemporary circulating variants. Authorization is supported by cumulative clinical, non-clinical and real-world evidence.
- Pfizer Canada says it has secured sufficient inventory to meet contractual commitments with federal and provincial vaccination programs and is managing distribution to support access across Canada.
- The updated vaccine is expected to become available through various distribution channels in the coming days and weeks, including participating pharmacies for eligible individuals outside publicly funded programs.
Takeaways:
Health Canada’s authorization of the XFG‑adapted Comirnaty vaccine for the 2026–2027 season keeps Pfizer/BioNTech aligned with national recommendations to match contemporary Omicron lineages, supporting continued uptake in publicly funded programs and among eligible individuals accessing the shot through pharmacies. With Pfizer confirming sufficient inventory to meet federal and provincial contracts and managing distribution for equitable access, the update helps maintain Comirnaty’s position as a core option in Canada’s fall/winter vaccination strategy alongside other mRNA vaccines, even as overall demand has moderated compared with peak pandemic years.
Source: CA Newswire
